Differences in selective pressure on dhps and dhfr drug resistant mutations in western Kenya

Andrea M. McCollum, Kristan A. Schneider, Sean M. Griffing, Zhiyong Zhou, Simon Kariuki, Feiko Ter-Kuile, Ya Ping Shi, Laurence Slutsker, Altaf A. Lal, Venkatachalam Udhayakumar, Ananias A. Escalante

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: Understanding the origin and spread of mutations associated with drug resistance, especially in the context of combination therapy, will help guide strategies to halt and prevent the emergence of resistance. Unfortunately, studies have assessed these complex processes when resistance is already highly prevalent. Even further, information on the evolutionary dynamics leading to multidrug-resistant parasites is scattered and limited to areas with low or seasonal malaria transmission. This study describes the dynamics of strong selection for mutations conferring resistance against sulphadoxine-pyrimethamine (SP), a combination therapy, in western Kenya between 1992 and 1999, just before SP became first-line therapy (1999). Importantly, the study is based on longitudinal data, which allows for a comprehensive analysis that contrasts with previous cross-sectional studies carried out in other endemic regions. Methods. This study used 236 blood samples collected between 1992 and 1999 in the Asembo Bay area of Kenya. Pyrosequencing was used to determine the alleles of dihydrofolate reductase (dhfr) and dihydropterote synthase (dhps) genes. Microsatellite alleles spanning 138 kb around dhfr and dhps, as well as, neutral markers spanning approximately 100 kb on chromosomes 2 and 3 were characterized. Results: By 1992, the South-Asian dhfr triple mutant was already spreading, albeit in low frequency, in this holoendemic Kenyan population, prior to the use of SP as a first-line therapy. Additionally, dhfr triple mutant alleles that originated independently from the predominant Southeast Asian lineage were present in the sample set. Likewise, dhps double mutants were already present as early as 1992. There is evidence for soft selective sweeps of two dhfr mutant alleles and the possible emergence of a selective sweep of double mutant dhps alleles between 1992 and 1997. The longitudinal structure of the dataset allowed estimation of selection pressures on various dhfr and dhps mutants relative to each other based on a theoretical model tailored to P. falciparum. The data indicate that drug selection acted differently on the resistant alleles of dhfr and dhps, as evidenced by fitness differences. Thus a combination drug therapy such as SP, by itself, does not appear to select for "multidrug"-resistant parasites in areas with high recombination rate. Conclusions: The complexity of these observations emphasizes the importance of population-based studies to evaluate the effects of strong drug selection on Plasmodium falciparum populations.

Original languageEnglish (US)
Article number77
JournalMalaria Journal
Volume11
DOIs
StatePublished - 2012

Fingerprint

Tetrahydrofolate Dehydrogenase
Kenya
Alleles
Mutation
Pharmaceutical Preparations
Parasites
Population
Chromosomes, Human, Pair 3
Chromosomes, Human, Pair 2
Therapeutics
Plasmodium falciparum
Combination Drug Therapy
Drug Resistance
Microsatellite Repeats
Genetic Recombination
Malaria
Theoretical Models
Cross-Sectional Studies
Pressure
pyrimethamine drug combination fanasil

Keywords

  • Dihydrofolate Reductase
  • Dihydropterote synthase
  • Drug resistance
  • Malaria
  • Natural selection
  • Plasmodium
  • Selective sweep
  • Sulphadoxine-pyrimethamine

ASJC Scopus subject areas

  • Infectious Diseases
  • Parasitology

Cite this

McCollum, A. M., Schneider, K. A., Griffing, S. M., Zhou, Z., Kariuki, S., Ter-Kuile, F., ... Escalante, A. A. (2012). Differences in selective pressure on dhps and dhfr drug resistant mutations in western Kenya. Malaria Journal, 11, [77]. https://doi.org/10.1186/1475-2875-11-77

Differences in selective pressure on dhps and dhfr drug resistant mutations in western Kenya. / McCollum, Andrea M.; Schneider, Kristan A.; Griffing, Sean M.; Zhou, Zhiyong; Kariuki, Simon; Ter-Kuile, Feiko; Shi, Ya Ping; Slutsker, Laurence; Lal, Altaf A.; Udhayakumar, Venkatachalam; Escalante, Ananias A.

In: Malaria Journal, Vol. 11, 77, 2012.

Research output: Contribution to journalArticle

McCollum, AM, Schneider, KA, Griffing, SM, Zhou, Z, Kariuki, S, Ter-Kuile, F, Shi, YP, Slutsker, L, Lal, AA, Udhayakumar, V & Escalante, AA 2012, 'Differences in selective pressure on dhps and dhfr drug resistant mutations in western Kenya', Malaria Journal, vol. 11, 77. https://doi.org/10.1186/1475-2875-11-77
McCollum, Andrea M. ; Schneider, Kristan A. ; Griffing, Sean M. ; Zhou, Zhiyong ; Kariuki, Simon ; Ter-Kuile, Feiko ; Shi, Ya Ping ; Slutsker, Laurence ; Lal, Altaf A. ; Udhayakumar, Venkatachalam ; Escalante, Ananias A. / Differences in selective pressure on dhps and dhfr drug resistant mutations in western Kenya. In: Malaria Journal. 2012 ; Vol. 11.
@article{d64541d40ab34d3296c4f62020ea1611,
title = "Differences in selective pressure on dhps and dhfr drug resistant mutations in western Kenya",
abstract = "Background: Understanding the origin and spread of mutations associated with drug resistance, especially in the context of combination therapy, will help guide strategies to halt and prevent the emergence of resistance. Unfortunately, studies have assessed these complex processes when resistance is already highly prevalent. Even further, information on the evolutionary dynamics leading to multidrug-resistant parasites is scattered and limited to areas with low or seasonal malaria transmission. This study describes the dynamics of strong selection for mutations conferring resistance against sulphadoxine-pyrimethamine (SP), a combination therapy, in western Kenya between 1992 and 1999, just before SP became first-line therapy (1999). Importantly, the study is based on longitudinal data, which allows for a comprehensive analysis that contrasts with previous cross-sectional studies carried out in other endemic regions. Methods. This study used 236 blood samples collected between 1992 and 1999 in the Asembo Bay area of Kenya. Pyrosequencing was used to determine the alleles of dihydrofolate reductase (dhfr) and dihydropterote synthase (dhps) genes. Microsatellite alleles spanning 138 kb around dhfr and dhps, as well as, neutral markers spanning approximately 100 kb on chromosomes 2 and 3 were characterized. Results: By 1992, the South-Asian dhfr triple mutant was already spreading, albeit in low frequency, in this holoendemic Kenyan population, prior to the use of SP as a first-line therapy. Additionally, dhfr triple mutant alleles that originated independently from the predominant Southeast Asian lineage were present in the sample set. Likewise, dhps double mutants were already present as early as 1992. There is evidence for soft selective sweeps of two dhfr mutant alleles and the possible emergence of a selective sweep of double mutant dhps alleles between 1992 and 1997. The longitudinal structure of the dataset allowed estimation of selection pressures on various dhfr and dhps mutants relative to each other based on a theoretical model tailored to P. falciparum. The data indicate that drug selection acted differently on the resistant alleles of dhfr and dhps, as evidenced by fitness differences. Thus a combination drug therapy such as SP, by itself, does not appear to select for {"}multidrug{"}-resistant parasites in areas with high recombination rate. Conclusions: The complexity of these observations emphasizes the importance of population-based studies to evaluate the effects of strong drug selection on Plasmodium falciparum populations.",
keywords = "Dihydrofolate Reductase, Dihydropterote synthase, Drug resistance, Malaria, Natural selection, Plasmodium, Selective sweep, Sulphadoxine-pyrimethamine",
author = "McCollum, {Andrea M.} and Schneider, {Kristan A.} and Griffing, {Sean M.} and Zhiyong Zhou and Simon Kariuki and Feiko Ter-Kuile and Shi, {Ya Ping} and Laurence Slutsker and Lal, {Altaf A.} and Venkatachalam Udhayakumar and Escalante, {Ananias A.}",
year = "2012",
doi = "10.1186/1475-2875-11-77",
language = "English (US)",
volume = "11",
journal = "Malaria Journal",
issn = "1475-2875",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Differences in selective pressure on dhps and dhfr drug resistant mutations in western Kenya

AU - McCollum, Andrea M.

AU - Schneider, Kristan A.

AU - Griffing, Sean M.

AU - Zhou, Zhiyong

AU - Kariuki, Simon

AU - Ter-Kuile, Feiko

AU - Shi, Ya Ping

AU - Slutsker, Laurence

AU - Lal, Altaf A.

AU - Udhayakumar, Venkatachalam

AU - Escalante, Ananias A.

PY - 2012

Y1 - 2012

N2 - Background: Understanding the origin and spread of mutations associated with drug resistance, especially in the context of combination therapy, will help guide strategies to halt and prevent the emergence of resistance. Unfortunately, studies have assessed these complex processes when resistance is already highly prevalent. Even further, information on the evolutionary dynamics leading to multidrug-resistant parasites is scattered and limited to areas with low or seasonal malaria transmission. This study describes the dynamics of strong selection for mutations conferring resistance against sulphadoxine-pyrimethamine (SP), a combination therapy, in western Kenya between 1992 and 1999, just before SP became first-line therapy (1999). Importantly, the study is based on longitudinal data, which allows for a comprehensive analysis that contrasts with previous cross-sectional studies carried out in other endemic regions. Methods. This study used 236 blood samples collected between 1992 and 1999 in the Asembo Bay area of Kenya. Pyrosequencing was used to determine the alleles of dihydrofolate reductase (dhfr) and dihydropterote synthase (dhps) genes. Microsatellite alleles spanning 138 kb around dhfr and dhps, as well as, neutral markers spanning approximately 100 kb on chromosomes 2 and 3 were characterized. Results: By 1992, the South-Asian dhfr triple mutant was already spreading, albeit in low frequency, in this holoendemic Kenyan population, prior to the use of SP as a first-line therapy. Additionally, dhfr triple mutant alleles that originated independently from the predominant Southeast Asian lineage were present in the sample set. Likewise, dhps double mutants were already present as early as 1992. There is evidence for soft selective sweeps of two dhfr mutant alleles and the possible emergence of a selective sweep of double mutant dhps alleles between 1992 and 1997. The longitudinal structure of the dataset allowed estimation of selection pressures on various dhfr and dhps mutants relative to each other based on a theoretical model tailored to P. falciparum. The data indicate that drug selection acted differently on the resistant alleles of dhfr and dhps, as evidenced by fitness differences. Thus a combination drug therapy such as SP, by itself, does not appear to select for "multidrug"-resistant parasites in areas with high recombination rate. Conclusions: The complexity of these observations emphasizes the importance of population-based studies to evaluate the effects of strong drug selection on Plasmodium falciparum populations.

AB - Background: Understanding the origin and spread of mutations associated with drug resistance, especially in the context of combination therapy, will help guide strategies to halt and prevent the emergence of resistance. Unfortunately, studies have assessed these complex processes when resistance is already highly prevalent. Even further, information on the evolutionary dynamics leading to multidrug-resistant parasites is scattered and limited to areas with low or seasonal malaria transmission. This study describes the dynamics of strong selection for mutations conferring resistance against sulphadoxine-pyrimethamine (SP), a combination therapy, in western Kenya between 1992 and 1999, just before SP became first-line therapy (1999). Importantly, the study is based on longitudinal data, which allows for a comprehensive analysis that contrasts with previous cross-sectional studies carried out in other endemic regions. Methods. This study used 236 blood samples collected between 1992 and 1999 in the Asembo Bay area of Kenya. Pyrosequencing was used to determine the alleles of dihydrofolate reductase (dhfr) and dihydropterote synthase (dhps) genes. Microsatellite alleles spanning 138 kb around dhfr and dhps, as well as, neutral markers spanning approximately 100 kb on chromosomes 2 and 3 were characterized. Results: By 1992, the South-Asian dhfr triple mutant was already spreading, albeit in low frequency, in this holoendemic Kenyan population, prior to the use of SP as a first-line therapy. Additionally, dhfr triple mutant alleles that originated independently from the predominant Southeast Asian lineage were present in the sample set. Likewise, dhps double mutants were already present as early as 1992. There is evidence for soft selective sweeps of two dhfr mutant alleles and the possible emergence of a selective sweep of double mutant dhps alleles between 1992 and 1997. The longitudinal structure of the dataset allowed estimation of selection pressures on various dhfr and dhps mutants relative to each other based on a theoretical model tailored to P. falciparum. The data indicate that drug selection acted differently on the resistant alleles of dhfr and dhps, as evidenced by fitness differences. Thus a combination drug therapy such as SP, by itself, does not appear to select for "multidrug"-resistant parasites in areas with high recombination rate. Conclusions: The complexity of these observations emphasizes the importance of population-based studies to evaluate the effects of strong drug selection on Plasmodium falciparum populations.

KW - Dihydrofolate Reductase

KW - Dihydropterote synthase

KW - Drug resistance

KW - Malaria

KW - Natural selection

KW - Plasmodium

KW - Selective sweep

KW - Sulphadoxine-pyrimethamine

UR - http://www.scopus.com/inward/record.url?scp=84862819556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862819556&partnerID=8YFLogxK

U2 - 10.1186/1475-2875-11-77

DO - 10.1186/1475-2875-11-77

M3 - Article

VL - 11

JO - Malaria Journal

JF - Malaria Journal

SN - 1475-2875

M1 - 77

ER -